UPCOMING EVENTS
NEWS
St. Louis biotech KaloCyte joins UM BioPark, consolidates team in Baltimore
A St. Louis biotechnology company backed by $6 million in funding has relocated to a small space in one of the University of Maryland, Baltimore’s research facilities.
KaloCyte joins as an affiliate of the university’s BioPark, or biomedical research park, with the goal of bringing its synthetic red blood cell substitute to market. The product, called ErythroMer, is designed to take the place of blood in trauma situations or other times when it may be unavailable.
KaloCyte Relocates to Downtown Baltimore as Co-Founders Join University of Maryland Faculty
KaloCyte, a preclinical-stage healthcare biotechnology company developing a synthetic, bio-inspired red blood cell substitute for use in settings when stored red blood cells are not available, has joined Baltimore’s growing biotech community as a University of Maryland (UM) BioPark affiliate. KaloCyte’s relocation from St. Louis brings it closer to major stakeholders and funders, including the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute’s (NHLBI) Small Business Program and the U.S. Department of Defense (DoD) Army Combat Casualty Care Research Program, as well as the outstanding research and clinical communities at the University of Maryland, Baltimore (UMB) and University of Maryland, Baltimore County (UMBC) campuses.
Nationally-Recognized Physician-Scientist Allan Doctor Joins University of Maryland School of Medicine; Will Lead New Research Center
Steven J. Czinn, MD, The Drs. Rouben and Violet Jiji Endowed Professor and Chair, Department of Pediatrics at the University of Maryland School of Medicine (UMSOM), and Adnan T. Bhutta, MMBS, FAAP, Professor and Division Head in the UMSOM Department of Pediatrics,...
KaloCyte at the Medical Technology Enterprise Consortium (MTEC)
Elaine E. Haynes and Jennifer Richards represented KaloCyte, Inc. at the Medical Technology Enterprise Consortium (MTEC) 4th Annual Membership Meeting in Charleston last week. In more exciting news, Jennifer Richards’s submission efforts were rewarded, and Elaine E....
St. Louis startups take home prize money at Startup Connection
Nearly a dozen companies took home prizes at this year’s Startup Connection.
The annual event, held Wednesday at The Globe Building, 710 N. Tucker Blvd. in downtown St. Louis, featured dozens of startups in a wide variety of sectors including advanced manufacturing, bioscience, consumer products, education and technology. More than 60 startups were selected to present as part of the event’s Venture Showcase, competing for prizes that included cash, office space and professional services.
Which Startup Will Make It Big Starting At Startup Connection’s Tenth Anniversary Event?
What do Life Sciences company, Immunophotonics, video game studio Butterscotch Shenanigans, and protein-packed Belgian waffle Start Right Foods have in common? Yes, they are all examples of successful St. Louis startups. Immunophotonics has raised $4.3 million in six rounds. Butterscotch Shenanigans collected $1.4 million in revenue in 2017, Start Right Foods is on the brink of distributing their product nationally. But they all found early footing by participating in Startup Connection too. Startup Connection is St. Louis’ annual showcase of early stage startups. In 2018, Startup Connection celebrates their tenth anniversary on Wednesday, November 7 from 4:30-9:00 PM at The Globe Building in downtown St. Louis.
Health Care Q&A: Synthetic blood startup’s new CEO hopes to bring product to hospitals, battlefields and eventually Mars
St. Louis Business Journal By Brian Robbins From paramedics to soldiers, a synthetic blood substitute could change the health care industry. At least that’s what KaloCyte’s new CEO Elaine Haynes believes. Haynes, who was took the position in August, brings expertise...
Washington University researcher moves closer to perfecting artificial blood
St. Louis Business Journal By Brian Robbins June 25, 2018, 6:51 am A universal blood substitute has been one of the most elusive breakthroughs for medical researchers over the past 70 years, with companies attempting to create synthetic blood that can be easily...
St. Louis synthetic blood startup raises $800,000
St. Louis Business Journal By Brian Robbins June 4, 2018, 2:41 pm A biotech startup that is developing bio-synthetic hybrid red blood cells has raised $800,000 from investors, according to a Securities and Exchange Commission filing. KaloCyte Inc., founded in 2016 and...
Wash U continues quest to develop artificial blood
By Shahla Farzan Apr 13, 2018 Thousands of people in the United States die each year due to severe blood loss, often before they reach an emergency room. To help reduce the number of trauma deaths, a Washington University research team is working to develop an...
CONTACT US
KaloCyte, Inc.
4 N. Martin Luther King Jr. Blvd
Suite 300
Baltimore, MD 21201
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.